The efficacy of reducing agents or antioxidants in blocking the formation of dense cells and irreversibly sickled cells in vitro

Blood

Volumn 91, Issue 11, 1998, Pages 4373-4378

  Gibson, Xunda A ^a   Shartava, Archil ^a   McIntyre, Jonah ^a   Monteiro, Carlos A ^a   Zhang, Yalin ^a   Shah, Arvind ^a   Campbell, Naomi F ^a   Goodman, Steven R ^a  

^a UNIVERSITY OF SOUTH ALABAMA COLLEGE OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ACETYLCYSTEINE; ANTIOXIDANT; DIMERCAPROL; MERCAPTAMINE; REDUCING AGENT; SUCCIMER;

ANTIOXIDANT ACTIVITY; ARTICLE; CONTROLLED STUDY; DRUG EFFICACY; ERYTHROCYTE SHAPE; GLUTATHIONE METABOLISM; HUMAN; HUMAN CELL; PRIORITY JOURNAL; SICKLE CELL;

EID: 0032101033     PISSN: 00064971     EISSN: None     Source Type: Journal    
DOI: 10.1182/blood.v91.11.4373     Document Type: Article

References (30)

1. Fabry ME, Benjamin L, Lawrence C, Nagel RL: An objective sign in painful crises in sickle cell anemia: The concomitant reduction in high density red cells. Blood 64:559, 1984
2. Bertles JF, Milner PFA: Irreversibly sickled erythrocytes: A consequence of the heterogeneous distribution of hemoglobin types in sickled-cell anemia. J Clin Invest 47:1731, 1968
3. Kaul DK, Fabry ME, Nagel RL: Vaso-occlusion by sickle cells: Evidence for selective trapping of dense red cells. Blood 68:1162, 1986
4. Kaul DK, Fabry ME, Nagel RL: Microvascular sites and characteristics of sickle cell adhesion to vascular endothelium in shear flow conditions: Pathophysiological implications. Proc Natl Acad Sci USA 86:3356, 1989
5. Fabry ME, Fine E, Rajonayagam V, Factor SM, Gore J, Sylla M, Nagel RL: Demonstration of endothelial adhesion of sickle cells in vivo: A distinct role for deformable sickle cell discocytes. Blood 79:1602, 1992
6. Hebbel RP: The sickle erythrocyte in double jeopardy: Autoxidation and iron decompartmentalization. Semin Hematol 27:51, 1990
7. Hebbel RP: Beyond hemoglobin polymerization: The red blood cell membrane and sickle disease pathophysiology. Blood 77:214, 1991
8. Joiner CH: Cation transport and volume regulation in sickle red blood cells. Am J Physiol 264:C251, 1993
9. Goodman SR, Shifter K: The spectrin membrane skeleton of normal and abnormal human erythrocytes: A review. Am J Physiol 244:C121, 1983
10. Goodman SR, Krebs KE, Whitfield CF, Riederer BM, Zagon IS: Spectrin and related molecules. CRC Crit Rev Biochem 23:171, 1988
11. Shartava A, Monteiro CA, Bencsath FA, Schneider K, Chait BT, Gussio R, Casoria-Scott LA, Shah AK, Heuerman CA, Goodman SR: A posttranslational modification of β-actin contributes to the slow dissociation of the spectin-protein 4.1-actin complex of irreversibly sickled cells. J Cell Biol 128:805, 1995
12. Bencsath FA, Shartava A, Monteiro CA, Goodman SR: Identification of the disulfide-linked peptide in irreversibly sickled cell β-actin. Biochemistry 35:4403, 1996
13. Shartava A, Miranda P, Williams KN, Shah A, Monteiro CA, Goodman SR: High density sickle cell erythrocyte core membrane skeletons demonstrate slow temperature dependent dissociation. Am J Hematol 51:214, 1996
14. Shartava A, Korn W, Shah AK, Goodman SR: Irreversibly sickled cell β-actin: Defective filament formation. Am J Hematol 55:97, 1997
15. Goodman SR: The role of the membrane skeleton in formation of the irreversibly sickled cell: A review. Cell Mol Biol Lett 1:105, 1996
16. Jensen M, Shohet SB, Nathan DG: The role of red cell energy metabolism in the generation of irreversibly sickled cells in vitro. Blood 42:835, 1973
17. Ohnishi ST: Inhibition of the in vitro formation of irreversibly sickled cells by cepharanthine. Br J Haematol 55:665, 1983
18. McClave JT, Deitrich FH, Simcich T: Statistics. Englewood Cliffs, NJ, Prentice Hall, 1997
19. Kirk RE: Experimental Design. New York, NY, Brooks/Cole, 1995
20. Markello TC, Mernardine ME, Gahl WA: Improved renal function in children with cystinosis treated with cysteamine. N Engl J Med 328:1157, 1993
21. Aposhian HV, Aposhian MM: Meso-2,3-dimercaptosuccinic acid: Chemical, pharmacological and toxicological properties of an orally effective metal chelating agent. Am Rev Pharmacol Toxicol 30:279, 1990
22. Schwartz RS, Shartava A, Musto S, Nagel RL, Goodman SR: Slow dissociation rates of membrane cytoskeletons from hydrated irreversibly sickled cells. Presented at the 20th Meeting of the National Sickle Cell Programs Meeting, Boston, MA, March 18-21, 1995, Abstract No. 60
23. Hebbel RP, Eaton JW, Balasingam M, Steinberg MH: Spontaneous oxygen radical generation by sickle erythrocytes. J Clin Invest 70:1253, 1982
24. Kuross SA, Rank BH, Hebbel RP: Excess heme in sickle erythrocyte inside-out membranes: Possible role in thiol oxidation. Blood 71:876, 1988
25. Lanchant NA, Davidson WD, Tanaka KR: Impaired pentose phosphate shunt function in sickle cell disease: A potential mechanism for increased Heinz body formation and membrane lipid peroxidation. Am J Hematol 15:1, 1983
26. Wetterstroem N, Brewer GS, Warth JA, Mitchinson A, Wear K: Relationship of glutathione levels and Heinz body formation to irreversibly sickled cells in sickle cell anemia. J Lab Clin Med 103:589, 1984
27. Johnson RM, Ravindranath Y, El-alfy M, Goyette G Jr: Oxidant damage to erythrocyte membrane in glucose 6-phosphate dehydrogenase deficiency: Correlation with in vivo reduced glutathione concentration and membrane protein oxidation. Blood 83:1117, 1994
28. Ziment I: Acetylcysteine: A drug that is much more than a mucokinetic. Biomed Pharmacother 42:513, 1988
29. Meister A: Selective modification of glutathione metabolism. Science 220:142, 1983
30. Bernard GR, Wheeler AP, Arons, MM, Morris PE, Paz HL, Russell JA, Wright PE: A trial of antioxidants N-acetylcysteine and procysteine in ARDS. Chest 112:164, 1997